The overall survival rate for therapy-naive BRAF-mutated advanced melanoma patients is 34% after 5 years of combined targeted therapy with BRAF/MEK-inhibitors, whereas patients receiving a first-line immune checkpoint blockade showed an overall 5-year survival rate of 60% [5]. The gene discussed is MAP2K7; the disease is melanoma.